| It is a synthetic antineoplastic anthracenedione for intravenous use. Although its mechanism of action is not fully elucidated, it is a DNA - reactive agent. It has a cytocidal effect on with proliferating and non proliferating cultured small cells suggesting lock of cell cycle specifically.
| Composition : | 20mg/10ml | | Indications : | Mitoxantrone in combination with other approved drug (s) is indicated in the initial therapy of acute non lymphocytic leukemias (ANLL) in adults. This category includes myelogenous, promyelocyctic monocytic and erythroid acute leukemias. | | Contraindications : | The drug is contraindicated in patients demonstrating prior hypersensitivity. Severe myelosupression can occur when it is used in doses indicated for the treatment of leukemia.
Functional cardiac changes including congestive heart failure and decreases in left ventricular ejection fraction (LVEF) occur with mitoxantrone. Cardiac toxicity is more important in patients with prior treatment with anthracyclines, prior, mediastinal radiotherapy, or with prior treatment with anthracyclines, prior mediastinal radiotheraphy, or with pre-existing cardiovascular disease. | | Safety Profile : | History of cardiac disease, Periodic blood counts should be done and cardiac function should be monitored along with liver function tests.
Mitoxantrone may impart blue - Green color to the urine for 24 hours after administration bluish discoloration of sclera may also occur. | | Adverse Effects : | : Rash, dyspnoea, phlebitis cardiotoxicity which might manifest as CHF and arrhythmias. GI symptoms such as nausea, vomiting diarrhoea along with bone marrow suppression are also known. | | Drug Interactions: | Warfarin increases prothormbin time. | | Dosage : | Initially 14 mg / sqm body surface area as single i.v dose; repeat after 21 day interval. | | Purity : | Not less than 99%. |
|
 |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
